Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linvoseltamab versus continued daratumumab + lenalidomide + dexamethasone after DRd induction in transplant-ineligible newly diagnosed multiple myeloma
NL-OMON59773Phase 3Recruiting
- Sponsor
- European Myeloma Network B.V.
- Start
- Sep 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing DRd induction followed by linvoseltamab with Continued daratumumab + lenalidomide + dexamethasone (2 arms). Primary endpoints: MRD-negative complete response at 10^-5 and Progression-free survival. Started Sep 2025; status: recruiting.
02
Drugs
linvoseltamabdaratumumablenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON59773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59773.